AWM Investment Company Inc. boosted its stake in Corium International, Inc. (NASDAQ:CORI) by 1,125.9% during the first quarter, Holdings Channel reports. The fund owned 2,451,700 shares of the biopharmaceutical company’s stock after buying an additional 2,251,700 shares during the period. Corium International comprises about 1.9% of AWM Investment Company Inc.’s portfolio, making the stock its 17th largest position. AWM Investment Company Inc. owned about 0.08% of Corium International worth $10,248,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its stake in Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 13,683 shares during the last quarter. Geode Capital Management LLC boosted its stake in Corium International by 0.6% in the first quarter. Geode Capital Management LLC now owns 69,552 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 444 shares during the last quarter. Vanguard Group Inc. boosted its stake in Corium International by 44.1% in the first quarter. Vanguard Group Inc. now owns 500,965 shares of the biopharmaceutical company’s stock valued at $2,094,000 after buying an additional 153,358 shares during the last quarter. Royce & Associates LP boosted its stake in Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares during the last quarter. Finally, RTW Investments LLC boosted its stake in Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Institutional Ownership by Quarter for Corium International (NASDAQ:CORI)

Corium International, Inc. (NASDAQ:CORI) traded down 3.61% on Monday, reaching $6.94. 310,853 shares of the company’s stock were exchanged. The company’s market cap is $202.87 million. The firm has a 50 day moving average of $5.90 and a 200-day moving average of $4.55. Corium International, Inc. has a 12-month low of $2.67 and a 12-month high of $8.33.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.05. The business had revenue of $7.35 million during the quarter, compared to analyst estimates of $6.05 million. Corium International had a negative net margin of 116.59% and a negative return on equity of 1,550.00%. Equities analysts expect that Corium International, Inc. will post ($1.69) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/corium-international-inc-cori-stake-raised-by-awm-investment-company-inc/1356334.html.

A number of research analysts have weighed in on CORI shares. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Corium International in a research note on Friday, April 14th. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research note on Monday, June 5th. FBR & Co reissued an “outperform” rating and issued a $13.00 target price (up from $12.00) on shares of Corium International in a research note on Tuesday, April 18th. ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Jefferies Group LLC decreased their target price on shares of Corium International from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, February 15th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Corium International has an average rating of “Buy” and a consensus target price of $11.25.

In other Corium International news, major shareholder Perceptive Advisors Llc purchased 1,902,400 shares of the stock in a transaction dated Thursday, May 25th. The shares were acquired at an average cost of $6.25 per share, for a total transaction of $11,890,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 45.70% of the stock is owned by corporate insiders.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Want to see what other hedge funds are holding CORI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corium International, Inc. (NASDAQ:CORI).

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.